| Revenue growth | 70% YoY increase to ₹655 Cr in FY26 |
|---|---|
| Margins | EBITDA margin expanded from 1.04% to 3.22% YoY |
| Demand visibility | Strong traction in domestic and export segments across 12+ countries |
| Management confidence | High; citing strong operational momentum and efficiency |
Growth
Revenue grew 70% YoY to ₹655 Cr; EBITDA rose 423% to ₹21.11 Cr; PAT surged 2276% to ₹10.93 Cr.
Outlook
Capacity expansion via backward integration and dedicated plants for Amoxicillin and Cloxacillin to support future growth.
Risks
Regulatory compliance risks for WHO-GMP and deferred tax adjustments impacting quarterly profitability.
Earnings Call filed with BSE, NSE: SYSCHEM. Summary written with AI assistance from the document.
Syschem (India) Ltd: key numbers
- Share price
- ₹37.19
- Market cap
- ₹182.3 Cr
- Revenue (annual)
- ₹573.8 Cr
- Net profit (annual)
- ₹10.93 Cr
- P/E (TTM)
- 29.7×Sector 47.4×
- Promoter holding
- 63.38%+2.52% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Syschem (India) Ltd
All →Syschem (India) Annual General Meeting
Syschem (India) Limited issued its 33rd AGM notice for September 30, 2026. Key agendas include approving material related-party transactions and appointing statutory auditors.
Syschem (India) Annual Report
Syschem (India) Limited has filed its 33rd Annual Report for FY 2025-26. The company convened its Annual General Meeting for September 30, 2026.
Syschem (India) Board Meeting Outcome
Syschem (India) Limited clarified the statutory auditor's professional fee following its board meeting outcome. The proposed fee is set at ₹0.025 Crore plus applicable expenses.
- Value
- ₹0.03 Cr
Syschem (India) Management Change
M/s STAV & Co., Chartered Accountants, resigned as Statutory Auditor of Syschem (India) Limited effective August 31, 2026. The resignation follows the expiry of the firm's Peer Review Certificate.
Syschem (India) Results Correction
Syschem (India) Limited clarified a typographical error in its previously uploaded Investor Presentation. The correction changes references from 'Q2' to 'Q1' for Financial Year 2026-27.
Syschem (India) Investor Presentation: Key Takeaways
Syschem reported Q2 FY27 revenue moderation at ₹126 Cr vs ₹126.76 Cr YoY. Despite a net deficit and PBT loss of ₹145 Lakhs, operational stability was maintained through cost discipline.